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Background: Botulinum toxin A (BoNT-A) is a new treatment modality in various causes of bladder dysfunction; like
neurogenic detrusor overactivity and overactive bladder. The best technique of administrating BoNT-A in patients is
unknown. A validated in vitro model could be used to investigate newer intravesical administration techniques of
BoNT-A. In this study, we describe the development and validation of in vitro model to measure inhibitory effects
of BoNT-A on bladder strip contractions.
Methods: Rat bladder strips were mounted in organ baths filled with Krebs’ solution. The strips were stimulated
chemically (80 mM potassium chloride, 1 μM carbachol) and electrically (Electrical Field Stimulation (EFS) 100
shocks, 50 V, 20 Hz, every 3 minutes). The viability of the strips was measured by carbachol stimulation at the
beginning and at the end of the experiments. The strips were incubated in various concentrations of BoNT-A
(0.03, 0.2, 0.3 nM). Controls were incubated in Krebs’ solution only. The inhibition of strip contraction induced by
EFS was measured. These measurements were statistically analyzed with a log-logistic model representing diffusion.
Results: All strips remained viable during the experiments. Inhibition of strip contraction was observed after
incubation with 0.3 nM BoNT-A. The measurements fitted to a log-logistic model describing diffusion of BoNT-A in
the bladder strip. The parameters of the log-logistic model representing diffusion were significant for 0.3 nM
BoNT-A. Incubation with 0.2 nM BoNT-A showed insignificant results for 2 out of 3 runs. Incubation with 0.03 nM
BoNT-A did not result in significant inhibition of strip contractions.
Conclusions: An in vitro model was developed and validated in which the inhibitory effect of low concentrations
of BoNT-A on bladder strip contractions can be measured.
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Botulinum neurotoxin A (BoNT-A) was introduced for
the treatment of overactive bladder (OAB) by Schurch
et al. at the beginning of this century [1]. Since then, mul-
tiple clinical trials proved that BoNT-A is an effective
therapy for the treatment of refractory OAB [2]. How-
ever, these clinical trials demonstrated differences in effi-
cacy and duration of the response. The most effective
doses, volumes of dilution, numbers of injection and the* Correspondence: j_vanuhm@hotmail.com
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unless otherwise stated.best sites of injections needed for effective treatment are
not well known [3]. Despite evolving knowledge about
the mechanism of action of BoNT-A on neurotransmitter
release and receptor activation, the spread of BoNT-A
after intravesical injections remains unknown [4,5]. If we
would be able to monitor the spread of BoNT-A in the
bladder wall after administration, we might understand
the differences in clinical effect in patients. Furthermore,
we could develop the most favourable method of admin-
istrating BoNT-A in the bladder.
To gain insight into the mechanism of spread of
BoNT-A after injection in the bladder wall, we would
need a reliable in vitro model with reproducible results.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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BoNT-A in an in vitro model with rat bladder strips [6].
Howles et al. on the other hand could not reproduce
these measurements in another in vitro model [7].
Takahashi et al. demonstrated inhibitory effect of BoNT-A
in vitro however it was at a much higher concentration
(>10 nM) than is used in clinical practice (10 U/1 mL
onabotulinumtoxinA = 0.001 nM) [8]. In this study, we
further developed and validated an in vitro model to
measure the bioactivity of BoNT-A in lower concentra-
tions. To reach this goal, we sought for the best math-
ematical model to better understand the spread of
BoNT-A in a bladder strip.
Methods
Tissue preparation and strip tension measurement
Eight adult male Wistar rats (250–300 g, Harlan, The
Netherlands) were used. All experiments were per-
formed in accordance with institutional guidelines and
were approved by the ethics committee for animal ex-
periments of the VU University Amsterdam. The urinary
bladder was removed following isoflurane anaesthesia
and heart dissection of the rat. The bladder was immedi-
ately placed in Krebs’ solution (mmol/L; NaCl 113, KCl
4.8, MgSO4 1.2, KH2PO4 1.2, CaCl2*2H2O 2.5, NaHCO3
25, glucose 11.5, bubbled with 95% O2 and 5% CO2 to
attain a pH of 7.4) at 35 degrees Celsius.
Two longitudinal strips of maximally 0.7 by 7 mm
were cut from the dorsal side of the bladder body under
a microscope. The urothelial layer of the strips was me-
ticulously removed with micro scissors under dark field
illumination. The serosal layer of the bladder was not
removed.
The two rat bladder strips were mounted between 2
platinum hooks in two parallel organ baths. One of the
platinum hooks was connected directly to a force trans-
ducer (AE801, SensoNor, Norway) (Figure 1). The baths
were perfused with 35°C Krebs’ solution for 60 minutes
to stabilize the strips at a passive tension of 10 milli-
newton. Hereafter the bladder strips were stimulated.
Chemical stimulation was performed with 80 mM
potassium chloride (KCl) or 1 μM carbachol (CCh).
Between the chemical stimulations and during the
electrical field stimulation, the organ baths were per-
fused by Krebs’ solution. Electrical field stimulation
(EFS) between two platinum plate electrodes was deliv-
ered by a Grass SD9 stimulator. The intrinsic nerves
were stimulated with 50 V pulses of 100 shocks at a
frequency of 20 Hz. The stimulation interval was
3 minutes.
Before we started the BoNT-A experiments, we incu-
bated two strips in 1 μM tetrodotoxin (TTX) during
continuous EFS to verify that the EFS protocol induced
primarily nerve cell depolarization [9]. Subsequently, weincubated two strips in Krebs’ solution and gradually
lowered the oxygen tension in the organ bath from 95%
to 20%. We calculated the critical oxygen tension in the
organ bath by a Hill diffusion model previously de-
scribed by Van der Laarse et al. [10]. Contractions were
recorded by a data acquisition program (NEWXLC® soft-
ware developed by the Department of Physiology, VUmc,
Amsterdam).
Drugs and solutions
KCl, CCh, TTX and BoNT-A were obtained from Sigma-
Aldrich, Zwijndrecht, The Netherlands. The BoNT-A used
was pure BoNT-A (molecular weight of 150 kDa), i.e.
toxin without any enveloping proteins. KCL, CCh, TTX
and BoNT-A were all dissolved in Krebs’ solution. All so-
lutions were gassed with a mixture of 95% O2 and 5%
CO2 (pH 7.4 at 35°C).
Viability of bladder strips
To establish the viability of the bladder strips after prep-
aration and during the stimulation protocol, the strips
were excited chemically by adding 80 mM KCl and 1 μM
CCh to the organ baths. The organ baths were flushed
with Krebs’ solution after chemical stimulation. KCl in-
duces smooth muscle membrane depolarization without
the need of activation of any receptor or second messen-
ger system [9]. CCh induces contraction of the bladder
strip by direct activation of the muscarinic receptor at
the smooth muscle cell membrane. CCh interacts with
the same muscarinic receptor as acetylcholine [9]. BoNT-
A inhibits the release of acetylcholine and it does not
interact with the muscarinic receptor at the muscle cell
membrane. CCh still induces strip contraction after
BoNT-A incubation. The comparison of CCh-induced
strip contraction before and after BoNT-A incubation
acts as a viability test of this strip during the experiment.
Stimulation protocol
KCl and CCh were used to verify viability, while EFS
provided baseline contractions during phase 1. Organ
baths were perfused with 80 mM KCl for 10 seconds,
followed by flushing the organ baths with Krebs’ solution
for 3 minutes. This cycle was performed three times.
Subsequently, organ baths were perfused 3 times with
1 μM CCh solution followed by flushing the organ baths
with Krebs’ solution for 3 minutes. Finally, contractions
were induced by EFS (50 V, 20 Hz, 100 shocks) for five
times, each with an interval of 3 minutes.
In phase 2, strips were incubated in various concentrations
BoNT-A (0.03, 0.2, 0.3 nM). Control strips were perfused by
Krebs’ solution only. Repetitive EFS was performed.
Phase 3 consisted of perfusion of Krebs’ solution in the
organ baths for at least 5 minutes. Subsequently, repeti-





Krebs with 95% O2 / 5% CO2
+  80 mM KCl
+  1 µM CCh







Figure 1 Schematic representation of the in vitro model. The organ bath was continuously perfused with Krebs’ solution. Chemical
stimulation was performed by perfusion the bath with 80 mM KCl or 1 μM CCh and flushing the bath with Krebs’ solution in between. During
BoNT-A incubation, the bath was continuously perfused by the same concentration of BoNT-A (0.03, 0.2, 0.3 nM).
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performed. We refer further to a completed protocol of
stimulations as a ‘run’.
BoNT-A incubation
Each BoNT-A concentration was tested 3 times. Two
strips of the same bladder were incubated in 2 parallel
organ baths. One strip was incubated in 0.3 nM BoNT-
A (run 1a, 2a, 4a) whereas the other strip was perfused
with Krebs’ solution (=control: run 1b, 2b, 3b). To estab-
lish whether there was a minimum concentration neces-
sary to measure an inhibitory effect of BoNT-A inTable 1 The results of maximum inhibition of strip contractio
represents diffusion
BoNT-A (nM) run Imax CI m
0.3 1a 0.42 0.37-0.47 2.33
0.3 2a 0.62 0.46-0.77 1.49
0.3 4a 1.00 0.66-1.33 1.80
0.2 3a 0.99 0.61-1.37 2.08
0.2 4b 0.82 min 0.02- 1.65 2.43
0.2 5a 1.00 min 0.25-2.25 3.26
0.03 5b 0.06 0.05-0.08 1.19
0.03 6a 0.83 min 8.04-9.71 7.51
0 1b 0.02 min 17.7-17.7 0.52
0 2b 0.16 0.03-0.29 0.24
0 3b 0.01 min 19.4-19.4 2.70
The data with 95% confidence interval (CI) of calculated maximum of inhibition (Ima
predictive accuracy of the model (R2) of various BoNT-A concentrations during runbladder strip contractions, run 3a, 4b and 5a contained
strips incubated in 0.2 nM BoNT-A. Run 5b, 6a, 6b con-
tained strips incubated in BoNT-A 0.03 nM.
Data analysis
Three peak forces of strip contraction induced by CCh
stimulation were measured and averaged (mPF CCh).
The viability of the strip was established by the equation:
Contractility = mPF CCh phase III/mPF CCh phase I. A
strip is viable if contractility equals 1.
Inhibition of bladder strip contraction by BoNT-A was
measured by comparing the mean peak force induced byn calculated by a log-logistic model which
CI b CI R2
2.22-2.44 6.44 5.33-7.54 0.99
1.18-1.80 3.35 1.90-4.79 0.99
1.31-2.28 3.23 1.55-4.90 0.99
1.33-2.82 2.44 1.54-3.33 0.99
min 0.36-5.22 1.83 0.59-3.08 0.99
0.51-6.01 2.96 0.89-5.03 0.98
0.87-1.50 4.45 min 0.42-9.31 0.96
min 49.76-64.79 2.02 min 1.25-5.30 0.89
min 3304-3305 0.32 min 420-420 •
min 1.38-1.87 1.83 min 18.0-21.7 0.35
min 2067-2067 3.01 min 978-985 •
x), mid inhibition time in hours (m), shape parameter of the curve (b),
1 to 6. R2 could not be calculated for 0 nM during run 1b and run 3b.
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defined by: Inhibition = 1 – (mPF incub/mPF max), in
which mPF incub is the mean of five repetitive peak
forces by EFS measured every 30 minutes during incuba-
tion, and mPF max is the mean of five highest repetitive
peak forces of strip contractions induced by EFS at the
start of phase II.
We analyzed the data by a mathematical model repre-
senting diffusion, as we hypothesized that BoNT-ABoNT-A
incubation




Figure 2 A-B: Bladder strip contractions after BoNT-A incubation. A: R
before and after 0.3 nM BoNT-A incubation (run 1a). B: Response of bladde
perfusion (run 1b = control).spreads in the bladder strip by diffusion. The model is a
log-logistic model [11]: I = Imax/(1 + exp (− b * ln (t/m))),
where I = measured inhibition of contraction of bladder
strip, Imax = calculated maximum of inhibition, b = shape
parameter of the curve, t = time after highest peak forces
of EFS at start of incubation (hours), and m =mid inhib-
ition time, at which I = 0.5 Imax (hours). R
2 is predictive
accuracy of the model, so the closer R2 is to 1.0, the bet-
ter the data fit to the curve. The curve fits if R2 is moreEFS CCh
EFS CCh
esponse of bladder strip contraction force (mN) to KCl, CCh, EFS










Figure 3 A-C: Measured inhibition of bladder strip contraction and
fitted curves. Measured inhibition of bladder strip contraction after
incubation in 0 nM (control), 0.2 nM and 0.3 nM BoNT-A in time (hours)
with the fitted curves. Imax = calculated maximum of inhibition, b = shape
parameter of the curve, t = time after highest peak forces of EFS at start
of incubation (hours), m=mid inhibition time (hours), R2 = predictive
accuracy of the fitted curve. A= run 1 ∇= 0 nM (control), ●= 0.3 nM
BoNT-A. B= run 3 ∇= 0 nM (control), O = 0.2 nM BoNT-A. C= run 4
O= 0.2 nM BoNT-A, ●= 0.3 nM BoNT-A.
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and m are significant. Data analysis and curve fitting by
non-linear regression was done with SPSS 20®.
Results
Viability of bladder strips
Strip contraction induced by EFS decreased by more
than 90% after 1 μM TTX incubation. The oxygen ten-
sion in the organ bath was about 700 mmHg (pO2 95%)
and the critical oxygen tension during EFS was about
600 mmHg (pO2 80%) with a diameter of the strip of
maximally 0.7 mm.
All bladder strips contracted during perfusion of
80 mM KCl at the start of the runs. Median contractility
(mPF CCh phase III/mPF CCh phase I) of all strips was
1.1 (range 0.9 – 1.4). One strip (run 6b) was lost due to
technical problems.
BoNT-A effect on strip contractions
After incubation of strips in 0.3 nM BoNT-A, the Imax
was 0.42, 0.62 and 1.00 for run 1a, 2a and 4a respectively
(Table 1, Figures 2 and 3). R2 was 0.99. Respective mid
inhibition times (m) were 2.33 (95% C.I. = 2.22-2.44),
1.49 (95% C.I. = 1.18-1.80) and 1.80 (95% C.I. = 1.31-
2.28) hours. Shape parameters of the curve (b) were 6.44
(95% C.I. = 5.33-7.54), 3.35 (95% C.I. = 1.90-4.79) and
3.23 (95% C.I. = 1.55-4.90).
Incubation of strips in 0.2 nM BoNT-A solution dur-
ing run 3a, 4b and 5a showed incompatible results. Run
3a demonstrated a good fit of the curve with R2 = 0.99,
m = 2.08 (95% C.I. = 1.33-2.82) and b = 2.44 (95% C.I. =
1.54-3.33). However, run 4b and 5a had an insignificant
95% C.I. of m and b although R2 was good. BoNT-A
concentration of 0.03 nM did not induce inhibition of
strip contraction during run 5b and 6a, Imax was respec-
tively 0.06 (95% C.I. = 0.05-0.08) and 0.83 (95% C.I. =
min 8.04 – 9.71). No inhibition of strip contractions was
observed in the control runs (1b, 2b, 3b) using Krebs’
solution.
Discussion
In this study, an in vitro bladder strip model was vali-
dated to measure the spread and the inhibitory effects
of low concentrations of BoNT-A on bladder muscle
contractions. The spread of BoNT-A in bladder strips
could be reproduced and confirmed using a statistical
model representing diffusion at a concentration of 0.3
nM. A lower concentration of 0.2 nM showed inhibition,
however insignificant results for 2 out of 3 runs. The inhibi-
tory effects of BoNT-A on bladder strip contractions could
be demonstrated at lower concentrations than previously
described.
Smith et al. were the first to demonstrate inhibition of
bladder strips by BoNT-A in an in vitro model [6]. The
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protocols during incubation of the strips with BoNT-A.
Contractions of the strips did indeed decrease during in-
cubation, but viability of the strips was not measured
during the experiment. Howles et al. were unable to re-
produce in vitro muscle strip inhibition by BoNT-A [6]
In these experiments, the commercial products Botox®
(onabotulinumtoxinA = 900 kD) and Dysport® (abobotu-
linumtoxinA = 500 kD) were used, in which BoNT-A is
enveloped in large proteins [7]. These proteins might be
too large to diffuse through the luminal or serosal sur-
face of the bladder strips. Therefore we used pure
BoNT-A and also for this reason we removed the blad-
der mucosa from the strip before mounting the strip in
the organ bath, as did the group of Smith et al. [7].
To be sure that the EFS protocol primarily induces
nerve cell depolarization, strips were incubated in TTX
before applying EFS [9]. TTX selectively blocks the
sodium-channels in nerve cell membranes which effect-
ively inhibits nerve cell depolarization. Stimulation by
EFS after TTX incubation resulted in an almost complete
inhibition of strip contractions. In addition, we verified
that the oxygen tension was not limiting strip contraction
by keeping the oxygen tension in the organ bath higher
than the critical oxygen tension [10].
We demonstrated that the inhibitory effect of BoNT-A
at a concentration of 0.3 nM is the result of diffusion.
Incubation of strips with 0.2 nM BoNT-A demonstrated
equivocal diffusion results. Runs with lower concentra-
tions (0.03 nM) demonstrated no inhibition. This sug-
gested that there is a minimum BoNT-A concentration
needed for bladder muscle strip inhibition in vitro. We
demonstrated that the lowest effective concentration in
this setting lies between 0.2 and 0.3 nM.
It is self-evident that continuous perfusion of BoNT-A
in a bladder strip model is not directly comparable to
intravesical injections in patients. The much higher con-
centration needed in vitro (0.3 nM) compared to the
concentration needed in patients (onabotulinumtoxinA
10 U/mL = 0.001 nM) might be explained by the tech-
nique of administration. Moreover, the effect in vitro is
measured within a few hours after administration due to
susceptibility of the strip, whereas the effect of intravesi-
cal injections in patients becomes apparent after days or
weeks [3].
Our study completed the model of Smith et al. and
Takahashi et al. [6,8] by controlling the viability of the
bladder strips during the runs. We proved that the in-
hibitory effect of BoNT-A can be measured in vitro at
low concentrations. Furthermore, we postulated how
BoNT-A reaches the nerve endings in the musculus de-
trusor after injection. The statistical analysis suggests
that BoNT-A spreads through the muscle by diffusion.
Our results were significant for the highest concentrationused. For the lower concentration of 0.2 nM, curve fitting
was good, but parameters were insignificant. The spread
by diffusion can explain why BoNT-A acts best when
injected at multiple sides into the bladder wall. This
model can be used to study effectiveness of BoNT-A
using other techniques of administration such as elec-
tromotive administration [12,13] or intravesical delivery
using liposomes [14].
Conclusions
In this study we describe an in vitro model in which the
inhibitory effect of low concentration of BoNT-A on
bladder strip contractions can be measured. This model
can be used in the future to investigate newer intra-
vesical administration techniques of BoNT-A.
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